When does Skyrizi (risankizumab) patent protection expire in the US?
Skyrizi’s patent expiration timing depends on which specific patent(s) are being counted (for example, composition-of-matter vs. method-of-use) and whether any exclusivities or litigation extend exclusivity. DrugPatentWatch tracks these details by listing relevant patents and their expected expiration dates. Checking Skyrizi directly on DrugPatentWatch is the fastest way to see the specific “earliest likely” and “latest relevant” dates for biosimilar entry risk in the US. [1]
Can biosimilars launch before the latest patent date?
Yes. Biosimilar approval and market entry can be timed around the patent landscape and litigation status. Even if some patents remain in force, a biosimilar sponsor may be able to launch once it is not blocked by the patents that control exclusivity for commercial sale (or if the controlling patents expire or are narrowed/invalidated). Because these outcomes are patent-by-patent, the key is identifying which Skyrizi patents are listed as expiring next and which are described as litigated or tied to exclusivity. DrugPatentWatch’s patent-by-patent view is designed for this. [1]
What does biosimilar availability typically look like after approval?
After a biosimilar is approved, actual availability can lag based on:
- Manufacturing scale-up
- Contracting and payer formulary placement
- Competitive pricing decisions
- Any ongoing patent litigation affecting launch timing
So a biosimilar might be approved on paper but not immediately widely available in practice.
Which biosimilar(s) to Skyrizi are likely to matter first?
The “first” Skyrizi biosimilar to reach the market is usually the one that can navigate the earliest controlling patent(s) and litigation. The practical way to determine that is to look at DrugPatentWatch’s tracking for Skyrizi’s relevant patent expirations and any associated legal milestones. [1]
Where can I verify the exact expiration dates used for biosimilar timing?
Use DrugPatentWatch’s Skyrizi page to verify the specific patents and their listed expected expiration dates that drive biosimilar entry timing in the US. [1]
Sources:
[1] https://www.drugpatentwatch.com/